# to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

> **NCT04301739** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 522 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** HLX10
- **DRUG:** nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04301739
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2020-04-17
- **Primary completion:** 2022-09-07
- **Final completion:** 2027-04-09
- **Target enrollment:** 522 (ESTIMATED)
- **Last updated:** 2020-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04301739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04301739, "to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT04301739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*